Proscia and Johns Hopkins School of Medicine Collaborate to Bring AI Applications to High-Impact Diseases and Specialties in Pathology

Proscia, a provider of AI-enabled digital pathology software, and Johns Hopkins School of Medicine, one of the leading academic medical centers in the US, will collaborate on the development of computational applications that incorporate artificial intelligence (AI) to advance the practice of pathology for multiple diseases.

Disease-specific AI applications help drive efficiency, productivity, and quality in tissue diagnosis. This is critical in overcoming the subjectivity inherent in traditional pathology and in addressing the world’s looming pathologist shortage, according to Proscia. AI also has the power to tap into data unseen by the human eye to reveal clinically important tissue patterns.

Training a successful AI system for pathology requires diverse, high-quality pathology data. Diverse data helps ensure an AI system is accurate across a wide variety of diseases, methods of biopsy, preparation of tissue, tissue dying procedures, and digital scanning processes.

“As digital pathology continues to gain traction, AI-driven applications will advance this adoption by driving economic and clinical benefits,” says Dr. Michael Bonham, Chief Medical Officer of Proscia. “Proscia is proud to collaborate with Johns Hopkins School of Medicine, a leader in cancer research, diagnosis, and treatment, to accelerate our pipeline of disease-specific AI applications.”

This collaboration adds to the growing list of leading academic and commercial institutions with which Proscia has worked to bring disease-specific AI applications to market. Starting with its release of DermAI in June 2019, Proscia has grown its collaborators, which now include the University of Florida, Cockerell Dermatopathology, Dermatopathology Laboratory of Central States, and Thomas Jefferson University Hospital.*